Trametinib-13C,d3

Modify Date: 2024-01-10 11:28:32

Trametinib-13C,d3 structure	Common Name	Trametinib-13C,d3
	CAS Number	2712126-59-3	Molecular Weight	619.41
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₅₁₃CH₂₀D₃FIN₅O₄	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Trametinib-13C,d3

Trametinib-13C,d3 is the 13C- and deuterium labeled. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis[1][2].

Name	Trametinib-13C,d3

Description	Trametinib-13C,d3 is the 13C- and deuterium labeled. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. Trametinib activates autophagy and induces apoptosis[1][2].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer Signaling Pathways >> MAPK/ERK Pathway >> MEK Signaling Pathways >> Autophagy >> Autophagy
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[88].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223. [2]. Yamaguchi T, et al. Suppressive effect of an orally active MEK1/2 inhibitor in two different animal models for rheumatoid arthritis: a comparison with HWA486. Inflamm Res, 2012, 61(5), 445-454. [3]. Yamaguchi T, et al. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int J Oncol, 2011, 39(1), 23-31. [4]. Abe H, et al. Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate). ACS Med Chem Lett. 2011 Feb 28;2(4):320-4. [5]. Liu H, et al. Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple Negative Breast Cancer. Cancer Discov. 2018 Mar;8(3):354-369. [6]. Lai J, et al. Elimination of melanoma by sortase A-generated TCR-like antibody-drug conjugates (TL-ADCs) targeting intracellular melanoma antigen MART-1. Biomaterials. 2018 Sep;178:158-169.

Molecular Formula	C₂₅₁₃CH₂₀D₃FIN₅O₄
Molecular Weight	619.41

Trametinib-13C,d3

Use of Trametinib-13C,d3

Names

Trametinib-13C,d3 Biological Activity

Chemical & Physical Properties